Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
| Status: | Recruiting |
|---|---|
| Conditions: | Infectious Disease, HIV / AIDS, Endocrine |
| Therapuetic Areas: | Endocrinology, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 2 - 85 |
| Updated: | 1/17/2019 |
| Start Date: | May 6, 2009 |
| Contact: | Pamela A Angelus, R.N. |
| Email: | pam.angelus@nih.gov |
| Phone: | (240) 669-5549 |
Establishing Fibroblast-derived Cell Lines From Skin/Tissue Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Background:
- National Institutes of Health (NIH) researchers have been studying immune cells (white
blood cells) to better understand how the human body s defense system works and adjusts
or regulates itself, and how changes in this system can make a person sick.
- To study the cells of patients who have problems with their immune systems, researchers
would like to collect samples of skin cells from patients with immune system disorders
and compare them with skin cells taken from healthy volunteers. By studying these cells,
researchers hope to determine whether these cells can be modified to create a new kind
of personalized gene therapy that would attempt to cure immune diseases in the future.
Objectives:
- To obtain skin cells from patients with immune system disorders and from healthy
volunteers for research and comparison purposes.
Eligibility:
- Patients between the ages of 2 and 85 who have immune system disorders.
- Healthy volunteers between the ages of 18 and 85.
- Both groups will be selected from the eligible participants of existing NIH studies into
immune system disorders.
Design:
- Researchers may take up to two biopsies from participants arms, legs, abdomen, or back.
- The biopsy site will be numbed with local anesthetic and cleaned before the sample is
taken.
- The punch skin biopsy needle will be inserted into the skin and rotated to remove a
small circle of skin (approximately 1/4 to 3/8 of an inch across). The area will be
closed with bandages or stitches, and then covered with a dressing. Any stitches will be
removed in 7 to 10 days.
- Tissue samples collected in the study will be stored for future research.
- National Institutes of Health (NIH) researchers have been studying immune cells (white
blood cells) to better understand how the human body s defense system works and adjusts
or regulates itself, and how changes in this system can make a person sick.
- To study the cells of patients who have problems with their immune systems, researchers
would like to collect samples of skin cells from patients with immune system disorders
and compare them with skin cells taken from healthy volunteers. By studying these cells,
researchers hope to determine whether these cells can be modified to create a new kind
of personalized gene therapy that would attempt to cure immune diseases in the future.
Objectives:
- To obtain skin cells from patients with immune system disorders and from healthy
volunteers for research and comparison purposes.
Eligibility:
- Patients between the ages of 2 and 85 who have immune system disorders.
- Healthy volunteers between the ages of 18 and 85.
- Both groups will be selected from the eligible participants of existing NIH studies into
immune system disorders.
Design:
- Researchers may take up to two biopsies from participants arms, legs, abdomen, or back.
- The biopsy site will be numbed with local anesthetic and cleaned before the sample is
taken.
- The punch skin biopsy needle will be inserted into the skin and rotated to remove a
small circle of skin (approximately 1/4 to 3/8 of an inch across). The area will be
closed with bandages or stitches, and then covered with a dressing. Any stitches will be
removed in 7 to 10 days.
- Tissue samples collected in the study will be stored for future research.
This protocol is designed as an adjunct to other NIAID IRB approved protocols that allow for
genetic testing, which may include those that are screening protocols for patients with rare
primary immunodeficiency or immunodysregulation disorders. Patients deemed of sufficient
research interest after review of outside medical records, clinical evaluation, and testing
may be invited to participate in this study. Healthy volunteers will also be invited to
participate as a source of control samples for research testing. After consent and enrollment
into this study, skin punch biopsies will be obtained to establish dermal fibroblast cell
lines for research studies directed at understanding the genetic and biochemical bases of
these diseases. Cell lines will also be used to investigate the utility of induced
pluripotent stem cells (iPS) for lymphocyte derivation and targeted gene correction. The
nasal epithelial scrapings will be used for research purposes to grow out primary nasal
respiratory epithelial cell lines. These cell lines will be used for functional studies by
testing virus replication in them. These functional studies will allow us to identify new
primary immunodeficiencies that may present primarily as recurrent or persistent lower
respiratory tract virus infections.Results with the potential to impact medical care will be
relayed to the referring physicians and where applicable, patients will be referred to other
appropriate NIH protocols for additional clinical evaluation and treatment. The study will
enroll up to 200 patients and healthy volunteers over the next 5 years.
genetic testing, which may include those that are screening protocols for patients with rare
primary immunodeficiency or immunodysregulation disorders. Patients deemed of sufficient
research interest after review of outside medical records, clinical evaluation, and testing
may be invited to participate in this study. Healthy volunteers will also be invited to
participate as a source of control samples for research testing. After consent and enrollment
into this study, skin punch biopsies will be obtained to establish dermal fibroblast cell
lines for research studies directed at understanding the genetic and biochemical bases of
these diseases. Cell lines will also be used to investigate the utility of induced
pluripotent stem cells (iPS) for lymphocyte derivation and targeted gene correction. The
nasal epithelial scrapings will be used for research purposes to grow out primary nasal
respiratory epithelial cell lines. These cell lines will be used for functional studies by
testing virus replication in them. These functional studies will allow us to identify new
primary immunodeficiencies that may present primarily as recurrent or persistent lower
respiratory tract virus infections.Results with the potential to impact medical care will be
relayed to the referring physicians and where applicable, patients will be referred to other
appropriate NIH protocols for additional clinical evaluation and treatment. The study will
enroll up to 200 patients and healthy volunteers over the next 5 years.
- INCLUSION CRITERIA:
Patients:
To be enrolled in this study, a patient must be greater than or equal to 2 years of age but
not greater than 85 years of age, have a known diagnosis of primary immunodeficiency or
immunodysregulation (or be a blood relative of such as patient), and be concurrently
enrolled on an NIAID IRB approved protocol that includes genetic testing for disease of the
immune system, such as but not limited to 05-I-0213 or 06-I-0015.
Healthy Volunteers:
To be enrolled in this study, a normal volunteer must fulfill all of the following
criteria:
- 1. Be enrolled on protocol 05-I-0213.
- 2. Be a healthy adult of either sex and between ages of 18 years and 85 years
EXCLUSION CRITERIA:
Patients with a primary immunodeficiency or immunodysregulation disorder (or a blood
relative of such a patient) are not eligible to be in this trial if:
- 1. Platelet count less than 20,000/microL
- 2. Patient is hemodynamically unstable because of acute bleeding.
- 3. Any condition that, in the investigator s opinion, places the patient at undue risk
by participating in the study or limits the utility of the specimen to be obtained.
- 4. For Nasal Scraping: a history of turbinectomy or significant nasal pathology that
would preclude obtaining mucosal scrape biopsies.
A Healthy Volunteer is not eligible to be in this trial if he or she fulfills any of the
following criteria:
- 1. Less than 18 years old or older than 85 years
- 2. Weighs less than 110 pounds
- 3. Is pregnant or breastfeeding
- 4. Is receiving a chemotherapeutic agent(s) or has a malignancy
- 5. Cannot avoid taking aspirin or non-steroidal anti-inflammatory medications during
the 7 days preceding skin biopsy
- 6. Have history of heart, lung, kidney disease, bleeding disorders, diabetes mellitus,
chronic peripheral arterial or venous insufficiency, chronic diffuse skin conditions
without uninvolved areas suitable for skin biopsy, poor skin healing, or keloid
formation.
- 7. Has been diagnosed as having viral hepatitis (B or C), human immunodeficiency virus
(HIV), or a carrier for methicillin-resistant Staphylococcus aureus (MRSA)
- 8. Hemoglobin measurement is less than 12.0 g/dL
- 9. Platelet count less than 150,000/(micro)L
- 10. PT greater than 15.0 seconds or PTT greater than 40 seconds
- 11. Has a history of intravenous injection drug use or of engaging in high-risk
activities for exposure to the acquired immunodeficiency syndrome (AIDS) virus.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Phone: 800-411-1222
Click here to add this to my saved trials
